

WuXi Biologics buys manufacturing facilities from Pfizer China

17 March 2021 | News

Quick access to high-demand DS and DP capacities and complement WuXi Biologics' existing network in China to address surging commercial manufacturing demands



WuXi Biologics, a global company with leading open-access biologics technology platforms, has announced that it has entered into an equity agreement with Pfizer China to acquire its state-of-the-art biologics manufacturing facilities as well as its labor force in Hangzhou, China.

The transaction is expected to close in the first half of 2021, which will immediately boost the commercial Drug Substance (DS) and Drug Product (DP) capacities for WuXi Biologics to address surging manufacturing demands.

The state-of-the-art 50,000 m² facilities, GMP operational since 2018, includes DS capacities equipped with 2x2000L single-use bioreactors expandable to 4x2000L (MFG20) and DP capacities of vial filling (DP9) and pre-filled syringe (DP10).

Leveraging the facilities' experienced workforce and WuXi Biologics' extensive expertise in manufacturing and regulation, the production is expected to commence shortly after the deal closure.

Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are pleased to work with Pfizer and add the new Hangzhou biologics manufacturing facilities to our global network to address the surging manufacturing demands for late-stage and commercial projects due to the success of our Win-the-Molecule strategy. Globally DS and especially DP capacities are in urgent need now. The acquisition will allow us to better enable our global partners to develop and manufacture premier-quality biologics to benefit patients around the world."